Posterior cortical atrophy in the age of anti-amyloid treatments: An 11-year retrospective study of eligible patients from the Leenaards Memory Center.

Abstract

At the era of the anti-amyloid treatments (AAT), it is striking to note posterior cortical atrophy (PCA) cases, the most predictive phenotype of Alzheimer's disease neuropathology, have not been explicitly included or excluded from clinical trials. In a retrospective analysis of the Leenaards Memory Center registry, we identified 41 PCA cases and, applying the recent appropriate use recommendations for lecanemab, estimate high (20%) eligibility rate, that doubles in pure PCA phenotypes with biomarker work-up available (40%). This high proportion of PCA patients eligible for AAT should prompt a timely exploration to assess inclusion/exclusion criteria for these novel therapies.